Aligos Therapeutics (ALGS) Study Result summary
Event summary combining transcript, slides, and related documents.
Study Result summary
8 Jul, 2026Study design and methodology
Phase 2a/2B HERALD study was a randomized, double-blind, placebo-controlled trial in 102 adults with MASH and liver fibrosis stages F1-F3 at 32 US centers, with four dose groups (0.3–0.9 mg) and placebo for 12 weeks.
Only subjects over 85 kg were enrolled in the 0.9 mg group to address body weight variability.
Primary endpoint was relative change in liver fat content by MRI-PDFF at Week 12; secondary endpoints included safety, tolerability, pharmacokinetics, and biomarker changes.
Baseline characteristics were generally balanced across arms, including age, BMI, diabetes prevalence, and liver fat content.
Study enrolled rapidly over six weeks, reflecting high interest in MASH therapies.
Efficacy and biomarker results
Statistically significant, dose-dependent reductions in liver fat by MRI-PDFF at week 12 in 0.5, 0.7, and 0.9 mg groups, with up to 46.2% placebo-adjusted median reduction at 0.7 mg.
Up to 70% of subjects in higher dose groups achieved ≥30% relative reduction in liver fat, predictive of histologic improvement.
Significant reductions in atherogenic lipids (LDL-C, lipoprotein(a), apolipoprotein B) and dose-related increase in SHBG were observed.
ALG-055009 showed greater liver fat reduction compared to published data for resmetirom, though no head-to-head trials were conducted.
The 0.7 mg and 0.9 mg doses showed the greatest efficacy, with p-values <0.001 versus placebo.
Safety and tolerability
ALG-055009 was well tolerated, with no serious adverse events or clinical evidence of hyper- or hypothyroidism.
Most treatment-emergent adverse events were mild or moderate; one discontinuation occurred due to insomnia.
No clinically meaningful lab, ECG, or vital sign abnormalities were observed.
Incidence of gastrointestinal events, including diarrhea, was similar or lower than placebo and lower than the approved comparator.
Favorable tolerability profile supports potential for long-term use in MASH treatment.
Latest events from Aligos Therapeutics
- Pevifoscorvir sodium shows strong clinical promise for HBV, backed by robust financials and partnerships.ALGS
Corporate presentation - $27.8M licensing revenue and pipeline milestones improved Q2 loss; cash runway into Q4 2026.ALGS
Q2 2026 - Q1 2026 saw a $23M net loss, China licensing deal, and cash runway into Q4 2026.ALGS
Q1 2026 - Annual meeting to vote on directors, auditor, stock plan amendment, and executive pay proposals.ALGS
Proxy filing - Proxy seeks approval for director elections, auditor, ESPP amendment, and executive pay votes.ALGS
Proxy filing - Pevifoscorvir sodium and ALG-055009 show strong clinical and commercial potential in HBV and MASH.ALGS
Corporate presentation - Pevifoscorvir sodium achieves superior HBV suppression and safety, with strong regulatory support.ALGS
Corporate presentation - Clinical and financial progress achieved, with pivotal HBV data expected in 2027.ALGS
Q4 2025 - Pevi delivers deep, durable HBV suppression with no resistance, setting a new clinical benchmark.ALGS
Jefferies London Healthcare Conference 2025